Effect of Omega-3 Fatty Acid Supplementation on Oxylipins in a Routine Clinical Setting
AbstractOmega-6 polyunsaturated fatty acid (n-6 PUFA) is the predominant polyunsaturated fatty acid (PUFA), especially in Western diet. A high omega-6/omega-3 ratio in Western diets is implicated in the development of cardiovascular diseases and inflammatory processes. Studies in animal models and in humans have demonstrated beneficial effects of omega-3 PUFA (n-3 PUFA) in a variety of diseases, including cardiac arrhythmias and inflammatory diseases, as well as breast and colon cancer. The molecular mechanisms underlying the effects of n-3 PUFA are still not well understood. Possible mechanisms include competition between n-3 and n-6 PUFAs at the cyclooxygenase (COX) and lipoxygenase (LOX) and cytochrome P450 levels, and subsequent formation of oxylipins with specific anti-inflammatory or anti-arrhythmic effects. In this study, we report the impact of routine long-term treatment with prescription-grade n-3 PUFA (either 840 mg or 1680 mg per day) on blood cell membrane fatty acid composition, as well as plasma oxylipin patterns, in a patient population with severe hyperlipidemia and cardiovascular disease who are on standard lipid-lowering and cardioprotective medications. Lipidomics analyses were performed by LC/ESI-MS/MS. Supplementation led to a dose-dependent increase in n-3 PUFA eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in the blood cell fraction. We also observed a dose-dependent increase in EPA- and DHA-derived epoxy metabolites, whereas the effect of n-3 PUFA supplementation on LOX-dependent EPA- and DHA-derived hydroxy metabolites was less pronounced, with a tendency towards lower metabolites in subjects with higher n-3 PUFA levels. These data thus generally confirm effects of n-3 PUFA supplementation observed previously in healthy individuals. Additionally, they indicate a suppressive effect of high n-3 PUFA supplementation on the formation of LOX metabolites in the context of concomitant aspirin medication. View Full-Text
- Supplementary File 1:
PDF-Document (PDF, 74 KB)
Share & Cite This Article
Schmöcker, C.; Zhang, I.W.; Kiesler, S.; Kassner, U.; Ostermann, A.I.; Steinhagen-Thiessen, E.; Schebb, N.H.; Weylandt, K.-H. Effect of Omega-3 Fatty Acid Supplementation on Oxylipins in a Routine Clinical Setting. Int. J. Mol. Sci. 2018, 19, 180.
Schmöcker C, Zhang IW, Kiesler S, Kassner U, Ostermann AI, Steinhagen-Thiessen E, Schebb NH, Weylandt K-H. Effect of Omega-3 Fatty Acid Supplementation on Oxylipins in a Routine Clinical Setting. International Journal of Molecular Sciences. 2018; 19(1):180.Chicago/Turabian Style
Schmöcker, Christoph; Zhang, Ingrid W.; Kiesler, Stefanie; Kassner, Ursula; Ostermann, Annika I.; Steinhagen-Thiessen, Elisabeth; Schebb, Nils H.; Weylandt, Karsten-H. 2018. "Effect of Omega-3 Fatty Acid Supplementation on Oxylipins in a Routine Clinical Setting." Int. J. Mol. Sci. 19, no. 1: 180.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.